TRIACETIN
Molecular Excipient
| Mwt. | LogP | HBD | HBA | PSA | RB | CSP3 |
|---|---|---|---|---|---|---|
| 218.0 | 0.0 | 0 | 6 | 79.0 | 5 | 0.67 |
- CAS
- 102761
- UNII
- XHX3C3X673
- SYNONYMS
-
- ZINC ID(s)
- Availability
- Present in 49 ZINC catalogs
Known Active Genes
There has not been any activity reported at 10μM or less for this excipient (per ChEBML)
Clinical Trials
This compound has been an intervention in the following clincial trials (per clinicaltrials.gov).
| Code | Date | Title | Phase | Status |
|---|---|---|---|---|
| NCT00657748 | 2009-09-01 | Lithium and Acetate for Canavan Disease | Phase 2 | Suspended |
(Browse) Purchasable Analogs in ZINC
Functions of Triacetin
| Misc - Miscellaneous |
Regulatory Status of Triacetin
| Gras - Generally recognized as safe. |
Dosages
| Route | Formulation | Per Unit Dose |
|---|---|---|
| Endocervical | Gel | |
| Oral | Capsule | 3.24MG |
| Oral | Capsule, Coated Pellets | 1.21MG |
| Oral | Capsule, Enteric Coated Pellets | 5.1MG |
| Oral | Capsule, Extended Release | 12.75MG |
| Oral | Capsule, Sustained Action | 2.76MG |
| Oral | Powder, For Oral Suspension | 0.02% |
| Oral | Suspension | 0.85MG |
| Oral | Tablet (immed./comp. Release), Film Coated | 0.72MG |
| Oral | Tablet, Coated | 1MG |
| Oral | Tablet, Delayed Action, Enteric Coated | 6MG |
| Oral | Tablet, Extended Release | 1.56MG |
| Oral | Tablet, Film Coated | 15.12MG |
| Oral | Tablet, Sustained Action | 1.96MG |
| Transdermal | Patch | 22.1MG |
| Transdermal | Patch, Controlled Release | 22.1MG |